Anovent Pharmaceutical

Anovent Pharmaceutical is a clinical-stage biopharmaceutical company specializing in the development of advanced inhalation therapies for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Based in Suzhou, China, the company utilizes its proprietary technology platforms for dry powder inhalers (DPI), pressurized metered-dose inhalers (pMDI), and soft mist inhalers to develop high-quality respiratory medicines. Anovent's pipeline features a range of complex generics and innovative combination therapies aimed at providing more effective and accessible treatment options for patients globally. The company is supported by leading healthcare investors and maintains a strong focus on formulation science and device engineering. By integrating drug formulation with device design, Anovent aims to overcome the high technical barriers associated with inhalation drug delivery.